Xcelom Limited (Global)
About Us
Xcelom Limited
Founded in 2014 by Professor Dennis Lo Yuk Ming and team, Xcelom is a genomics services provider and Hong Kong's largest NIPT provider operating under CUHK patent licenses.
Our parent company, Berry Genomics, is China's second largest NIPT provider and the first to translate long-read sequencing into clinical use, with 350,000+ clinical LRS cases. We serve healthcare providers, laboratories, and organizations with reliable solutions across markets.
Xcelom is the authorized sole representative of Berry Genomics for overseas business operations and the authorized distributor for Haorui Genomics laboratory solutions.
The Risk is NOT Knowing
Mission
Deliver innovative genomic services to our community
Vision
Pioneer the genomic service industry
Philosophy
Genome decoding makes impossible early detection possible
Global Business
Our portfolio covers sequencing-based screening and molecular diagnostics, including prenatal testing, carrier screening, and rare disease applications. We offer send-out testing, co-develop assays, and provide scalable end-to-end technology transfer so services can be run in-house. Deliverables include assay development, reagents, technical support and training, and bioinformatics/reporting/management software, supported by strong R&D capabilities and proven operational experience.
Business Profilo
Authorized distributor of Berry Genomics & Haorui Genomics solution
End-to-end technology transfer
Certified manufacturing bases in Hangzhou and Fuzhou
Send-out testing
With our affiliated labs accredited to ISO 13485, CAP and others
Co-develop customized service
Supported by our strong R&D capabilities
Distributing Excellence: Our Partners
Berry Genomics
Building on a strategic PacBio collaboration since 2017, Berry Genomics (贝瑞基因) leads the industry in clinical LRS applications on carrier screening and rare diseases:
Key Milestones and Achievements:
-
Innovation: Developed and launched CATSA, the first LRS-based thalassemia clinical assay (2021).
-
Proven Scale: These LRS assays have been performed in over 400,000 clinical cases and cited in more than 65 publications.
-
Regulatory Firsts: Achieved the first complete IVD approval (NMPA and/or CE-IVD) for the full LRS workflow, including the kit, the LRS sequencer(Sequel II CNDx), and analysis software.
Haorui Genomics
Founded in 2019, Haorui Genomics (西安浩瑞基因技术有限公司) specializes in applying LRS to clinical transplantation and transfusion. Their portfolio includes self-developed molecular solutions for HLA and blood group typing (ABO, Rh, etc.) with the proprietary TransMatch™ analysis platform, delivering a complete end-to-end solution.